TY - JOUR
T1 - Survival and prognostic factors after adjuvant 131iodine-labeled lipiodol for hepatocellular carcinoma
T2 - a retrospective analysis of 106 patients over 20 years
AU - Olesinski, Jonathan
AU - Mithieux, François
AU - Guillaud, Olivier
AU - Hilleret, Marie Noëlle
AU - Lombard-Bohas, Catherine
AU - Henry, Luc
AU - Boillot, Olivier
AU - Walter, Thomas
AU - Partensky, Christian
AU - Paliard, Pierre
AU - Valette, Pierre Jean
AU - Vuillez, Jean Philippe
AU - Borson-Chazot, Françoise
AU - Scoazec, Jean Yves
AU - Dumortier, Jérôme
N1 - Publisher Copyright:
© 2017, The Japanese Society of Nuclear Medicine.
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Objective: Hepatocellular carcinoma (HCC) has high recurrence rate after curative treatment. The aim of the present study was to report our experience with adjuvant use of 131I-lipiodol after curative treatment of HCC in terms of recurrence and survival in a large cohort of patients with a long follow-up. Methods: All patients treated with 131I-lipiodol after curative treatment of HCC in two French centers from 1991 to 2009 were included in a retrospective cohort study. Results: One hundred and six patients were included. The median (range) follow-up was 6 years (0.3–22). Forty-three patients (41%) had cirrhosis. Recurrence-free survival rates at 1, 2, 5, 10, and 20 years were 73, 57, 40, 30, and 14%, respectively. Cirrhosis was an independent predictive factor of recurrence [RR = 1.18, 95% CI (1.11–3.02), p = 0.019]. Overall, survival rates at 1, 2, 5, 10, and 20 years were 90, 83, 59, 37, and 23%, respectively. Prognostic factors were recurrence [RR = 2.73, 95% CI (1.35–5.54); p = 0.005], age over 60 years (RR = 1.91, 95% CI [1.02–3.61]; p = 0.044), and tumor number over 3 [RR = 3.31, 95% CI (1.25–8.77); p = 0.016]. Conclusion: Our results suggest that the effect of 131I-lipiodol after curative treatment of HCC could be related to a beneficial impact on risk factors of early tumor recurrence. This could be evaluated in further studies using modern radioembolization methods.
AB - Objective: Hepatocellular carcinoma (HCC) has high recurrence rate after curative treatment. The aim of the present study was to report our experience with adjuvant use of 131I-lipiodol after curative treatment of HCC in terms of recurrence and survival in a large cohort of patients with a long follow-up. Methods: All patients treated with 131I-lipiodol after curative treatment of HCC in two French centers from 1991 to 2009 were included in a retrospective cohort study. Results: One hundred and six patients were included. The median (range) follow-up was 6 years (0.3–22). Forty-three patients (41%) had cirrhosis. Recurrence-free survival rates at 1, 2, 5, 10, and 20 years were 73, 57, 40, 30, and 14%, respectively. Cirrhosis was an independent predictive factor of recurrence [RR = 1.18, 95% CI (1.11–3.02), p = 0.019]. Overall, survival rates at 1, 2, 5, 10, and 20 years were 90, 83, 59, 37, and 23%, respectively. Prognostic factors were recurrence [RR = 2.73, 95% CI (1.35–5.54); p = 0.005], age over 60 years (RR = 1.91, 95% CI [1.02–3.61]; p = 0.044), and tumor number over 3 [RR = 3.31, 95% CI (1.25–8.77); p = 0.016]. Conclusion: Our results suggest that the effect of 131I-lipiodol after curative treatment of HCC could be related to a beneficial impact on risk factors of early tumor recurrence. This could be evaluated in further studies using modern radioembolization methods.
KW - Adjuvant therapy
KW - Hepatocellular carcinoma
KW - Iodine-lipiodol, survival
UR - http://www.scopus.com/inward/record.url?scp=85016034527&partnerID=8YFLogxK
U2 - 10.1007/s12149-017-1165-4
DO - 10.1007/s12149-017-1165-4
M3 - Article
C2 - 28342103
AN - SCOPUS:85016034527
SN - 0914-7187
VL - 31
SP - 379
EP - 389
JO - Annals of Nuclear Medicine
JF - Annals of Nuclear Medicine
IS - 5
ER -